JPMorgan analyst Anupam Rama raised the firm’s price target on Neurocrine Biosciences to $139 from $134 and keeps an Overweight rating on the shares. The analyst updated the company’s model to reflect new Ingrezza revenue assumptions, expenses, and share count.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine announces settlement of INGREZZA ANDA litigation
- Neurocrine price target lowered to $121 from $128 at RBC Capital
- Neurocrine price target lowered to $100 from $111 at BMO Capital
- Neurocrine price target lowered to $114 from $116 at Mizuho
- Neurocrine price target lowered to $137 from $145 at BofA